TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26275735
Drug: Chemoradiotherapy (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (3 cycles of neoadjuvant chemotherapy: 100 mg/m² cisplatin and 85 mg/m² docetaxel followed by radiotherapy with 44 Gy in 22 fractions over 3 weeks)
Study: 23242470
Drug: pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pimecrolimus cream 1%
Study: 23242470
Drug: mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mometasone furoate (1 mg/g)
Study: 21319944
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg and esomeprazole magnesium 20 mg fixed-dose combination (FDC) twice daily for 12 months
Study: 17126628
Drug: Caloric beverage
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric beverage (increased portion size from 360 g/12 fl oz to 540 g/18 fl oz)
Study: 8472523
Drug: Meclofenamic acid
Normalized name: Meclofenamic Acid
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamic acid (200 mg b.i.d.)
Study: 3718377
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg scopolamine
Study: 3718377
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg scopolamine with 5 mg d-amphetamine
Study: 3718377
Drug: Scopolamine and
Normalized name: butylscopolamine and analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine and scopolamine with d-amphetamine (after discontinuation on day 5)
Study: 27261817
Drug: ZP‐025 (Monurelle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZP‐025 (Monurelle Biogel®) vaginal gel, 1 or 2 times/daily intra‐vaginally for about 23 intermenstrual days
Study: 27261817
Drug: ZP‐025 (Monurelle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZP‐025 (Monurelle Biogel®) vaginal gel
Study: 27261817
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment, lubricants on demand allowed)
Study: 22755467
Drug: Sequential practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential practice (implicit first and then explicit)
Study: 21084037
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment (FK506)
Study: 21084037
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate ointment (MPA)
Study: 21084037
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (MPA + FK506)
Study: 18295469
Drug: levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.125% with fentanyl 1 microg/mL at 8 mL/h
Study: 18295469
Drug: bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.125% with fentanyl 1 microg/mL at 8 mL/h
Study: 18295469
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.2% with fentanyl 1 microg/mL at 8 mL/h
Study: 11936565
Drug: Immediate-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release formulation (500 mg IR)
Study: 11936565
Drug: Modified-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release formulation (500 mg MR)
Study: 11936565
Drug: Modified-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release formulation (750 mg MR)
Study: 2140331
Drug: Josamycin 500
Normalized name: josamycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin 500 mg three times daily
Study: 6815790
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methylprednisolone (control)
Study: 6238861
Drug: C 48.401‐Ba
Approvals — FDA: no, EMA: no, PMDA: no
Description: C 48.401‐Ba cream (0.05% halomethasone)
Study: 6238861
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing 0.05% halomethasone
Study: 6238861
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing 0.1% betamethasone valerate
Study: 6238861
Drug: C 48.401‐Ba
Approvals — FDA: no, EMA: no, PMDA: no
Description: C 48.401‐Ba ointment (0.05% halomethasone)
Study: 27548106
Drug: Pulsatile cortisol
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile cortisol infusion
Study: 27548106
Drug: Mifepristone (GR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (GR antagonist)
Study: 27548106
Drug: Eplerenone (MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (MR antagonist)
Study: 27548106
Drug: Withdrawal vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal vs addback of sex steroids
Study: 19268928
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clomiphene citrate (25 mg/day) and vitamin E (400 mg/day)
Study: 19268928
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clomiphene citrate and vitamin E
Study: 16115336
Drug: Danish meat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danish meat diet (60 g of pork meat)
Study: 16115336
Drug: Polish meat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polish meat diet (60 g of pork meat)
Study: 10026394
Drug: UVA irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA irradiation at low dose (20 J/cm2)
Study: 10026394
Drug: UVA irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA irradiation at high dose (60 J/cm2)
Study: 10026394
Drug: UVA irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA irradiation (both doses)
Study: 7473528
Drug: Phosphoramidon (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphoramidon (combined inhibitor of endothelin converting enzyme and neutral endopeptidase)
Study: 7473528
Drug: Thiorphan (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiorphan (selective inhibitor of NEP)
Study: 30022753
Drug: rhTPO +
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO + DXM treatment
Study: 30022753
Drug: DXM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DXM treatment
Study: 22380743
Drug: (R)-warfarin
DrugBank: (S)-Warfarin (DB14055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-warfarin
Study: 22380743
Drug: (S)-warfarin
Normalized name: (S)-Warfarin
DrugBank: (S)-Warfarin (DB14055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-warfarin
Study: 22380743
Drug: Protein binding
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein binding of (R)- and (S)-warfarin
Study: 17213239
Drug: Assertive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive therapy (standing on the fractured limb and walking in parallel bars)
Study: 17213239
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (immobilization under skin traction and gradual use of a wheelchair)
Study: 11244392
Drug: Focused short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused short-term group therapy (10 sessions of 1.5 hours per week)
Study: 11244392
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received group therapy 5 months after the first group)
Study: 9227716
Drug: Pre-inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-inhalation of LTD4
Study: 9227716
Drug: Pre-inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-inhalation of methacholine
Study: 7678684
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg b.i.d. titrated to 75 mg)
Study: 7678684
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR (120 mg q.d. titrated to 360 mg)
Study: 2889081
Drug: Intramuscular recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular recombinant alpha 2‐interferon (r‐IFN) ('Roferon') 10 X 10(6) IU/m2 thrice weekly for 12 weeks
Study: 28521579
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) - 8 weekly sessions
Study: 19399268
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (cetrorelix 0.25 mg/day) until the day of hCG administration (Group A, 66 cycles)
Study: 19399268
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (cetrorelix 0.25 mg/day) until the day before hCG administration (Group B, 26 cycles)
Study: 16890670
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg toremifene
Study: 14728938
Drug: HIT-91 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HIT-91 therapy
Study: 14521705
Drug: 5% coal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% coal tar ointment
Study: 8811478
Drug: Supplementary surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary surgery or chemotherapy
Study: 1529416
Drug: Pinacidil 12.5
Normalized name: pinacidil 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 12.5 mg
Study: 15020520
Drug: Pinacidil 25
Normalized name: pinacidil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 25 mg
Study: 3908727
Drug: S6472 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: S6472 (750 mg, 2 times/day)
Study: 3908727
Drug: Cefaclor (CCL)
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor (CCL) (500 mg, 3 times/day)
Study: 3908727
Drug: Cephalexin (CEX)
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (CEX) (500 mg, 4 times/day)
Study: 30675739
Drug: levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: levomilnacipran ER (40, 80, or 120 mg/d)
Study: 25363118
Drug: Reality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reality therapy
Study: 23102380
Drug: Bivalirudin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin + Gp IIb/IIIa inhibitor (tirofiban)
Study: 23102380
Drug: UFH +
Normalized name: Unfractionated Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UFH + Gp IIb/IIIa inhibitor (tirofiban)
Study: 16519386
Drug: Standard Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Propofol (average particle size 193.3 nm) with 2 ml NaCl 0.9%
Study: 16519386
Drug: Standard Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Propofol (average particle size 193.3 nm) with 2 ml lidocaine 2%
Study: 16519386
Drug: Small particle
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small particle size lipid emulsion of Propofol (Anepol: average particle size 140.5 nm) with 2 ml NaCl 0.9%
Study: 16519386
Drug: Small particle
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small particle size lipid emulsion of Propofol (Anepol: average particle size 140.5 nm) with 2 ml lidocaine 2%
Study: 10356941
Drug: Vitamin supplement
Normalized name: Vitamin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplement (Vitality Roeder 2000 Junior)
Study: 7644858
Drug: High titre
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titre vaccines
Study: 4030162
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose (7:00 a.m.)
Study: 4030162
Drug: Evening dose
Normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dose (7:00 p.m.)
Study: 29747311
Drug: Paclitaxel for
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel for injection (albumin bound) (PAB)
Study: 29747311
Drug: Paclitaxel for
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel for injection (albumin bound) (PAB) as first-line therapy
Study: 29747311
Drug: Paclitaxel for
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel for injection (albumin bound) (PAB) as non-first-line therapy
Study: 29747311
Drug: Paclitaxel for
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel for injection (albumin bound) (PAB) in taxane-naïve patients
Study: 29747311
Drug: Paclitaxel for
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel for injection (albumin bound) (PAB) in taxane-pretreated patients
Study: 29747311
Drug: Abraxane (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abraxane (reference drug)
Study: 23740477
Drug: 120 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/day Eleutherococcus senticosus root extract (ES)
Study: 23740477
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both (COM)
Study: 21123766
Drug: Atorvastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 40 mg/day
Study: 19652945
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.8 g kg(‐1) day(‐1))
Study: 19652945
Drug: Normal-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein diet (1.2 g kg(‐1) day(‐1))
Study: 17960012
Drug: TPF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF (docetaxel and cisplatin on day 1; fluorouracil by continuous infusion, days 1 to 5)
Study: 8373716
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg twice daily for 3 days
Study: 8373716
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg twice daily
Study: 28033693
Drug: Morphine suppository
Normalized name: morphine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine suppository (10 mg)
Study: 10669898
Drug: Diclofenac suppository
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository (100 mg)
Study: 18712029
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate lotion 0.05%
Study: 18712029
Drug: OTC anti‐itch
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC anti‐itch preparation containing benzyl alcohol
Study: 14513648
Drug: Triptorelin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 0.1 mg subcutaneously daily for 7 days starting on day 21 of menstrual cycle
Study: 14513648
Drug: Buserelin intranasal
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin intranasal spray (long protocol)
Study: 10371363
Drug: Nurse-community health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-community health worker team in combination with usual medical care (SI)
Study: 6816316
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of endocrine and chemical therapies
Study: 28686808
Drug: CenteringPregnancy Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CenteringPregnancy Oral Health Promotion intervention (two 15-minute skills-based educational modules)
Study: 21130446
Drug: 400‐μg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400‐μg sublingual misoprostol plus routine uterotonics
Study: 21130446
Drug: 400‐μg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400‐μg sublingual misoprostol
Study: 9834799
Drug: CC (clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (clinical criteria)
Study: 7857516
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 300 mg hypericum extract
Study: 799996
Drug: Butorphanol tartrate
Normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butorphanol tartrate (1, 2, and 4 mg)
Study: 799996
Drug: Pentazocine lactate
Normalized name: Pentazocine Lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine lactate (30 and 60 mg)
Study: 25964369
Drug: Mandatory daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory daily hand washing before lunch
Study: 22282730
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement (54 patients)
Study: 8056998
Drug: lorazepam 0.5
Normalized name: lorazepam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 0.5 mg
Study: 18668226
Drug: lorazepam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 1.0 mg
Study: 14581110
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion for 90 minutes
Study: 14581110
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of S-ketamine
Study: 4051686
Drug: Paraprofessional drug
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraprofessional drug counseling alone
Study: 27981431
Drug: enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: enzalutamide 160 mg/day
Study: 25720808
Drug: Marbofloxacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marbofloxacin (2 mg/kg, IV, once; MRFX group)
Study: 25720808
Drug: Enrofloxacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrofloxacin (5 mg/kg, IV, once; ERFX group)
Study: 25720808
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline solution 0.9% NaCl, 10 ml, IV, once)
Study: 25720808
Drug: Marbofloxacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marbofloxacin (2 mg/kg, IV, once; MRFX group) and Enrofloxacin (5 mg/kg, IV, once; ERFX group)
Study: 19873912
Drug: Linggui Bafa
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linggui Bafa acupuncture treatment
Study: 19873912
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no acupuncture or oral medication)
Study: 15304576
Drug: Serum fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum fibrinogen levels >523 mg/dL
Study: 9762782
Drug: Formoterol 72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 72 microg (4+4+4 doses)
Study: 9762782
Drug: Terbutaline 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 6 mg (4+4+4 doses)
Study: 9762782
Drug: Formoterol 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 120 microg (8+6+6 doses)
Study: 9762782
Drug: Terbutaline 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 10 mg (8+6+6 doses)
Study: 2894490
Drug: Intravenous APSAC
Normalized name: APSAC
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous APSAC (30 unit dose)
Study: 30068306
Drug: Gentamicin-collagen sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-collagen sponge with systemic antibiotic therapy
Study: 30068306
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics alone (Control)
Study: 26825817
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids (IVF)
Study: 26825817
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fluids (IVF)
Study: 19925497
Drug: Immediate-release omeprazole
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release omeprazole 40 mg suspension o.m. for 7 days
Study: 19925497
Drug: Delayed-release omeprazole
Normalized name: omeprazole Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release omeprazole 40 mg capsule o.m. for 7 days
Study: 17917501
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg plus amlodipine 5 mg
Study: 8290195
Drug: Piperacillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (3 g every 6 hours) and Tazobactam (375 mg every 6 hours)
Study: 8290195
Drug: Clindamycin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (900 mg every 8 hours) and Gentamicin (2.5-5.0 mg/kg/day in three divided doses)
Study: 3187936
Drug: 135 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 g of canned mackerel paste (experimental group)
Study: 5763957
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of phenylpropanolamine taken orally
Study: 5763957
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of phenylpropanolamine taken orally
Study: 5763957
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of phenylpropanolamine taken orally (in a subject taking tranylcypromine)